Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, copy of Postal Ballot Notice dated May 16, 2025 along with the explanatory statement, seeking approval of the members of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has sent out a Postal Ballot Notice seeking shareholder approval to re-appoint Dr. Pankaj Shah (DIN: 02836324) as Managing Director & CEO for another 3-year term, from August 1, 2025 to July 31, 2028. The proposed remuneration is Rs. 60 lakh per annum, unchanged from his current pay, which has been at the same level since FY2022-23. Dr. Shah is 65 years old, holds 5 lakh equity shares in the company, and has over 43 years of experience in pathology. E-voting runs from June 11 to July 10, 2025, with results expected by July 12, 2025. The company noted it is passing this as a Special Resolution under Section 197 because it has been reporting losses (FY2024 PAT of Rs. 267.22 lakh loss, FY2023 PAT of Rs. 8.87 lakh loss).
This is a routine leadership continuity decision with no change in CEO or remuneration, so it is unlikely to move the stock. However, shareholders may note the disclosure that the company has been loss-making and is taking steps to improve liquidity and margins.